Liquid Biopsy Tools, Diagnostics Market to Reach $4.5B by 2022

October 11, 2017

WELLESLEY, Mass., Oct.11, 2017 – Liquid biopsy is rapidly gaining traction as a supplement or alternative to tissue biopsy, with the potential to attain a global market value of $4.5 billion by 2022. In a newly updated report from BCC Research, the industry’s prospects and technologies are studied for noncancer and cancer applications.

The liquid biopsy captures and analyzes biomarkers (mostly cell-free DNA) found in body fluids, usually blood. Liquid biopsy has applications in reproductive health, cancer and transplant medicine. In the noninvasive prenatal testing market, liquid biopsy has achieved significant penetration in the high-risk pregnancy segment and is moving into the low-risk sector. In cancer, liquid biopsy is gaining significant market traction. Payors are being influenced by mounting clinical data that support the use of liquid biopsy, and an emerging tissue-agnostic labeling strategy for cancer drugs is driving the use of liquid biopsy companion diagnostics. From an estimated $229.3 million in 2017 global sales, liquid biopsy applications in cancer are poised to contribute the greatest growth, at a compound annual growth rate of 52.4%, according to the report Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets.

Another high-potential sector for liquid biopsy is organ transplantation. In this market, there is a strong need for noninvasive diagnostics that can detect the early onset of organ rejection.

Research Highlights

  • Key growth sectors in the liquid biopsy cancer market include tests for lung cancer, pan-cancer tests that detect recurrence and tests that provide real-time assessment of disease progression.
  • Liquid biopsy is a key tool for assessing whether a patient is taking the right drug.
  • The global noncancer market is forecast to grow at a compound annual growth rate of 15.2% to reach $2.6 billion by 2022.

“The liquid biopsy industry is dynamic and gaining substantial traction in its three main clinical market segments," said John Bergin, BCC Research analyst and author of the report. "Circulating cell-free DNA is fast emerging as the predominant biomarker for liquid biopsy. This creates a market opportunity for companies who have or can develop proprietary technologies for improving the workflow for capturing, detecting and analyzing this biomarker type.”

Emerging Liquid Biopsy Companion Diagnostics

In May 2017, the U.S. FDA expanded its approval of pembrolizumab for treatment of advanced cancer with microsatellite instability or mismatch repair deficiency. This highlights a new paradigm in cancer care, where treatment is based on specific genomic defects rather than the organ of origin. This will boost the market for molecular diagnostics that can detect these genomic markers and be used to guide treatment decisions.

Editors/reporters requesting analyst interviews should contact

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets( BIO150B )
Publish Date: Sep 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.